- Home
- Equipment
- usa massachusetts
- microbiome
Show results for
Refine by
Microbiome Equipment Supplied In Usa Massachusetts
23 equipment items found
Manufactured by:AOBiome Therapeutic, LLC based inCambridge, MASSACHUSETTS (USA)
The human microbiome consists of hundreds of trillions of microorganisms, outnumbering human cells by 10 to 1 with as many as 3 million bacterial genes to our approximately 20 thousand. While the microbiome has recently become an area of active research, its overall effects on human health remain largely ...
Manufactured by:DermBiont, Inc. based inBoston, MASSACHUSETTS (USA)
A microbe is quite simply a microscopic organism. Microbes can be single-celled or comprise clusters of cells. They even include very small animals and other multicellular organisms; many are colonial and assume forms in nature that are easily visible to the naked eye. Microbes can be classified into four discrete ...
Manufactured by:Ardigen based inKraków, POLAND
We solve your problems by combining our expertise into the Ardigen Microbiome Translational ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-109 is a first-in-class investigational microbiome therapeutic administered orally following antibiotics to reduce recurrence of C. difficile infection (CDI) in patients with recurrent ...
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
CP101, an orally administered, Complete Consortia product candidate in late-stage clinical development for the prevention of recurrent C. difficile infection is also being developed for the treatment of chronic HBV. Chronic HBV infection occurs when the initial immune response fails to clear the virus, and may result in inflammation of hepatocytes, and complications including cirrhosis, liver ...
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
In collaboration with Takeda Pharmaceuticals, we are developing FIN-524 and FIN-525, orally administered, Targeted Consortia product candidates designed for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD), respectively. UC and CD are the two most common types of IBD, an autoimmune condition that causes inflammation of the gastrointestinal (GI) ...
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
FIN-211 is an orally administered, Enriched Consortia product candidate designed to address both the gastrointestinal (GI) and behavioral symptoms of ASD. ASD is a behaviorally defined condition characterized by difficulties with interpersonal interaction, communication, and repetitive or restrictive patterns of behavior and activities. A subset of individuals with ASD experience significant GI ...
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
Our lead product candidate, CP101, is an orally administered, Complete Consortia product candidate initially targeting the prevention of recurrent CDI. The Centers for Disease Control and Prevention considers CDI to be one of the top three most urgent antibiotic resistant threats and the most common cause of healthcare associated infection in the United ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-155 is an investigational, oral, rationally designed, fermented microbiome therapeutic designed to reduce the incidence of gastrointestinal infections, bacteremia, and graft versus host disease (GvHD) in immunocompromised patients, including patients receiving allogeneic hematopoietic stem cell transplantation ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-287 is an investigational, oral, biologically-derived microbiome therapeutic for the treatment of ulcerative colitis (UC). SER-287 is a consortium of multiple bacterial spores manufactured by fractionating and purifying targeted bacteria from stool of healthy human donors. SER-287 has been granted Fast Track designation and Orphan Drug designation by the FDA. ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-301 is an investigational, oral, rationally-designed, fermented microbiome therapeutic for the treatment of mild-to-moderate ulcerative colitis (UC). SER-301 is a consortium of multiple bacterial strains that is manufactured by fermenting each strain individually and then combining to form drug product. ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Our first-in-class keystone single-strain biotherapies address the root causes of the disease by regenerating a healthy microbiome, with subsequent deep beneficial effect on ...
Manufactured by:DermBiont, Inc. based inBoston, MASSACHUSETTS (USA)
leverage cutting edge innovation in dermatology and proprietary technology to efficiently develop targeted small molecule therapeutics and novel microbiome-based therapeutics for dermatologic indications that address the root cause of skin diseases. Our in-house discovery platform for microbiome-based therapeutics is enabled by terabytes of DNA sequencing data ...
Manufactured by:DermBiont, Inc. based inBoston, MASSACHUSETTS (USA)
We are focused on developing therapies that treat diseases of the skin at their root cause and fulfill the unmet needs of patients living with skin conditions. Our unique insights into the skin microbiome enable our discovery and clinical efforts. ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso4 is an exploratory program targeting the gut-brain axis for the treatment of mood disorders. Over the last 5 years, there has been increasing evidence that the gut microbiome was associated with neurological and behavioral disorders, which led to the so called “gut-brain axis” ...
Manufactured by:Adiso Therapeutics based inConcord, MASSACHUSETTS (USA)
It is bactericidal toward Clostridioides difficile and degrades Toxins A and B produced by C. difficile while maintaining other components of the microbiome. ADS024 is a single strain multimodal LBP and is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from donor fecal material. ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
The goal of our disruptive approach is to return to obese patients christensenella, which have the unique ability to repair the unbalanced microbiome, thereby restoring impaired key ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso5 is a discovery-stage program leveraging a specific keystone gut bacteria (undisclosed) to potentiate the effects of Immune Checkpoint Blockade (ICB) drugs. The field of cancer therapy has been revolutionized by the use of immunotherapy. The microbiome breakthrough science today paves the way for innovative biotherapies to potentiate the effectiveness of these cancer ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Using a revolutionary form of living biotherapy targeting the lung, YSOPIA is pioneering the innovative field of the lung microbiome. As part of this program, YSOPIA has selected a clinical candidate having demonstrated strong in vivo efficacy on inflammation and lung functions. We have achieved the formulation feasibility and cleared the regulatory hurdles associated with ...
Manufactured by:Gloveboxes Group based inAmesbury, MASSACHUSETTS (USA)
Leveraging automation technology, they ensure efficient, safe, and energy-optimized operations, making them suitable for handling nanoparticle drugs, microbiome science, and surgical ...